M&A / Deals Gilead outlays $5bn to acquire ADC specialist Tubulis Pharmaceutical TechnologySixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.M&A / DealsRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaceutical Technology Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs. M&A / DealsRead full story Post navigation Previous: Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist TubulisNext: Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026